A.G.P. Virtual Consumer Showcase
Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) A.G.P. Virtual Consumer Showcase summary

Event summary combining transcript, slides, and related documents.

Logotype for Niagen Bioscience Inc

A.G.P. Virtual Consumer Showcase summary

12 Nov, 2026

Business and research

  • Four business lines span consumer supplements and skincare, ingredient supply, Niagen Plus IV/injections, and pharmaceutical development.

  • Management cited 52 peer-reviewed clinical studies on NR and 30 more underway; it estimated the global NAD supplement market at $3B, versus $10M 8–10 years earlier.

  • Management positioned NR as its preferred NAD precursor and cited a Norway study finding NR 2.3x more effective than NMN at elevating NAD.

Consumer products and marketing

  • Tru Niagen is a ~$100M supplement, sold mainly through Amazon and its website, with Watsons in parts of Asia and limited U.S. retail; Nestlé and Life Extension also sell NR products.

  • Direct website sales grew more than 30% last year, while sales were flat this year amid lower-priced competitors; management expects supplement growth to resume as awareness and product range expand.

  • NanoCloud skincare launched after studies indicated topical NR penetrates skin and raises NAD in skin cells; management expects a major skincare partner to launch a widely distributed product in Q1 next year.

  • Marketing investment has increased and could remain elevated for one or two quarters; a Kelly Slater campaign is intended to build brand awareness.

Ingredient and delivery businesses

  • Ingredient customers include Nestlé, H&H, and Life Extension; a Goli NR gummy was expected to launch shortly.

  • Nicotinamide riboside malate is a lower-cost ingredient intended for broader supply to supplement brands; whether to launch it under Tru Niagen remained under review.

  • Niagen Plus offers pharmaceutical-grade NR through clinics and at-home injection kits; management described the kits as selling, while its plans for aggressive investment in the channel remained undecided.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Niagen Bioscience